№ lp_1_18228
File format: docx Character count: 4536 File size: 25 KB
Prospective clinical trial report presenting response rates, safety profile, and baseline characteristics of a fixed-duration BR plus Acalabrutinib regimen in untreated Waldenström’s Macroglobulinemia.
Year: 2024
Country: Canada
Study Type: Phase II clinical trial
Treatment Regimen: Bendamustine-Rituximab combination with concurrent Acalabrutinib
Participants: 62
Centers: 9
Primary Endpoint: Combined Complete and Very Good Partial Response (CR+VGPR) rates
Secondary Endpoints: Best overall response (BoR), progression-free survival (PFS), overall survival (OS), duration of response (DoR), Minimal Residual Disease (MRD)
Median Age: 69
Mutation Analysis: MYD88 89.3%, CXCR4 28.6%, TP53 1.8%
Adverse Events: Treatment-related adverse events (TRAEs) in 53 participants, 42 Grade 3/4 during combination therapy, 15 Grade 3/4 during monotherapy
Follow-up: Median 350 days
Data Cut-off: June 5, 2024
Document Type: Clinical trial report
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Single Cell multi-omics for minimally invasive assessment of Treatment efficacy in WMAssessing treatment efficacy is mandatory in Waldenström’s Macroglobulinemia (WM).
Year: 2022
Region / City: Pamplona, Spain
Topic: Research on Waldenström’s Macroglobulinemia treatment efficacy
Document Type: Research Article
Institution: University of Navarra, CIMA
Author: Bruno Paiva
Target Audience: Researchers in Hematology, Medical Professionals
Period of Validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Context: Research article on using flow cytometry for minimally invasive assessment of treatment efficacy in Waldenström’s Macroglobulinemia.
Topics: Bendamustine BRAWM Waldenstrms